CM
RNAM

Castleark Management’s Avidity Biosciences RNAM Stock Holding History

Castleark Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,620
Closed -$1.41M – 326
2025
Q1 		$1.41M Sell
47,620
-23,000
-33% -$716K 0.05% 202
2024
Q4 		$2.05M Buy
70,620
+13,510
+24% +$565K 0.07% 184
2024
Q3 		$2.62M Buy
+57,110
New +$2.48M 0.11% 162

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's RNAM Position: Q2 2025 in Review

Castleark Management sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 47,620 shares — an estimated $1.41M sold.

Castleark Management first reported a position in RNAM in Q3 2024 and held it in 3 quarters. The position peaked at $2.62M in Q3 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • Castleark Management reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • Castleark Management sold 47,620 Avidity Biosciences shares in Q2 2025, an estimated $1.41M.
  • Castleark Management first reported a position in Avidity Biosciences in Q3 2024 and held it in 3 quarters.
  • Castleark Management's Avidity Biosciences position peaked at $2.62M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Castleark Management's 13F filing for Q2 2025, filed 18 Aug 2025.